Atenolol vs. propranolol for the treatment of infantile haemangiomas: A systematic review and meta‑analysis

Liu,Zhuang; Wu,Changhua; Song,Dan; Wang,Liang; Li,Jing; Wang,Changfeng; Guo,Lei

doi:10.3892/etm.2020.8842

Atenolol vs. propranolol for the treatment of infantile haemangiomas: A systematic review and meta‑analysis

Authors:
- Zhuang Liu
- Changhua Wu
- Dan Song
- Liang Wang
- Jing Li
- Changfeng Wang
- Lei Guo
View Affiliations

Affiliations: Department of Vascular Anomalies and Interventional Radiology, Qilu Children's Hospital of Shandong University, Jinan, Shandong 250022, P.R. China
Published online on: June 5, 2020 https://doi.org/10.3892/etm.2020.8842
Pages: 1644-1652
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Infantile haemangioma (IH) is a benign vascular tumour type that occurs in 3‑10% of infants. In the present meta‑analysis, previous studies comparing clinical outcomes, including the recovery rate and haemangioma activity score (HAS), adverse effects and relapse rates, were compared between patients treated with atenolol and those treated with propranolol for IH. A systematic search in various databases, including Medline, Cochrane Controlled Register of Trials, ScienceDirect and Google Scholar from inception until July 2019 was performed. The Cochrane risk of bias tool was used to assess the quality of published trials. A meta‑analysis with a random‑effects model and reported pooled mean differences (MD) or odds ratios (OR) with 95% CIs was performed. In total, 8 studies including 608 participants were analyzed. Only 2 studies were randomized controlled trials, while the majority of studies had low or unclear bias risks. Except for the response to medication (pooled OR=1.49; 95% CI, 0.85‑2.18), all other outcomes (HAS, adverse reactions and relapse rate) were better for the atenolol group than the propranolol group. Atenolol resulted in better HAS (pooled MD=0.16; 95% CI, ‑0.42 to 0.73). Propranolol had more adverse reactions (pooled OR=2.17; 95% CI, 0.93‑5.06) and a higher relapse rate (pooled OR, 1.67; 95% CI, 0.44‑6.41) when compared to atenolol. However, these findings were not statistically significant. The results of this analysis suggest that atenolol may be non‑inferior to propranolol and may offer advantages, including lower adverse reactions and relapse rates.

View Figures

View References

1	Frieden IJ, Haggstrom AN, Drolet BA, Mancini AJ, Friedlander SF, Boon L, Chamlin SL, Baselga E, Garzon MC, Nopper AJ, et al: Infantile hemangiomas: Current knowledge, future directions Proceedings of a research workshop on infantile hemangiomas, April 7-9, 2005, Bethesda, Maryland, USA. Pediatr Dermatol. 22:383–406. 2005.PubMed/NCBI View Article : Google Scholar
2	Darrow DH, Greene AK, Mancini AJ and Nopper AJ: Section On Dermatology, Section On Otolaryngology-Head And Neck Surgery, and Section On Plastic Surgery. Diagnosis and management of infantile hemangioma. Pediatrics. 136:e1060–1104. 2015.PubMed/NCBI View Article : Google Scholar
3	Drolet BA, Frommelt PC, Chamlin SL, Haggstrom A, Bauman NM, Chiu YE, Chun RH, Garzon MC, Holland KE, Liberman L, et al: Initiation and use of propranolol for infantile hemangioma: Report of a consensus conference. Pediatrics. 131:128–140. 2013.PubMed/NCBI View Article : Google Scholar
4	Csoma ZR, Dalmády S, Ábrahám R, Rózsa T, Rácz K and Kemény L: Infantile haemangioma: Clinical and demographic characteristics, experiences in the treatment. Orv Hetil. 158:1535–1544. 2017.PubMed/NCBI View Article : Google Scholar : (In Hungarian).
5	Maturo S and Hartnick C: Initial experience using propranolol as the sole treatment for infantile airway hemangiomas. Int J Pediatr Otorhinolaryngol. 74:323–325. 2010.PubMed/NCBI View Article : Google Scholar
6	Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J, Guibaud L, Baselga E, Posiunas G, Phillips RJ, Caceres H, Lopez Gutierrez JC, Ballona R, et al: A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med. 372:735–746. 2015.PubMed/NCBI View Article : Google Scholar
7	Léaute-Labrèze C, Boccara O, Degrugillier-Chopinet C, Mazereeuw-Hautier J, Prey S, Lebbé G, Gautier S, Ortis V, Lafon M, Montagne A, et al: Safety of oral propranolol for the treatment of infantile hemangioma: A systematic review. Pediatrics. 138(e20160353)2016.PubMed/NCBI View Article : Google Scholar
8	Zhang L, Wu HW, Yuan W and Zheng JW: Propranolol therapy for infantile hemangioma: Our experience. Drug Des Devel Ther. 11:1401–1408. 2017.PubMed/NCBI View Article : Google Scholar
9	Raphael MF, Breur JM, Vlasveld FA, Elbert NJ, Liem YT, Kon M, Breugem CC and Pasmans SG: Treatment of infantile hemangiomas: Therapeutic options in regard to side effects and adverse events-a review of the literature. Expert Opin Drug Saf. 15:199–214. 2016.PubMed/NCBI View Article : Google Scholar
10	Léauté-Labrèze C, Harper JI and Hoeger PH: Infantile haemangioma. Lancet. 390:85–94. 2017.PubMed/NCBI View Article : Google Scholar
11	Chang L, Gu Y, Yu Z, Ying H, Qiu Y, Ma G, Chen H, Jin Y and Lin X: When to stop propranolol for infantile hemangioma. Sci Rep. 7(43292)2017.PubMed/NCBI View Article : Google Scholar
12	Raphaël MF, de Graaf M, Breugem CC, Pasmans SGMA and Breur JMPJ: Atenolol: A promising alternative to propranolol for the treatment of hemangiomas. J Am Acad Dermatol. 65:420–421. 2011.PubMed/NCBI View Article : Google Scholar
13	Ábarzúa-Araya A, Navarrete-Dechent CP, Heusser F, Retamal J and Zegpi-Trueba MS: Atenolol versus propranolol for the treatment of infantile hemangiomas: A randomized controlled study. J Am Acad Dermatol. 70:1045–1049. 2014.PubMed/NCBI View Article : Google Scholar
14	Bayart CB, Tamburro JE, Vidimos AT, Wang L and Golden AB: Atenolol versus propranolol for treatment of infantile hemangiomas during the proliferative phase: A retrospective noninferiority study. Pediatr Dermatol. 34:413–421. 2017.PubMed/NCBI View Article : Google Scholar
15	Wang Q, Xiang B, Chen S and Ji Y: Efficacy and safety of oral atenolol for the treatment of infantile haemangioma: A systematic review. Australas J Dermatol. 60:181–185. 2019.PubMed/NCBI View Article : Google Scholar
16	Liu X, Qu X, Zheng J and Zhang L: Effectiveness and safety of oral propranolol versus other treatments for infantile hemangiomas: A meta-analysis. PLoS One. 10(e0138100)2015.PubMed/NCBI View Article : Google Scholar
17	Novoa M, Baselga E, Beltran S, Giraldo L, Shahbaz A, Pardo-Hernandez H and Arevalo-Rodriguez I: Interventions for infantile haemangiomas of the skin. Cochrane Database Syst Rev. 4(CD006545)2018.PubMed/NCBI View Article : Google Scholar
18	Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J and Moher D: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. J Clin Epidemiol. 62:e1–e34. 2009.PubMed/NCBI View Article : Google Scholar
19	Higgins JP and Green S (eds.): Cochrane Handbook for Systematic Reviews of Interventions. John Wiley & Sons, Ltd., Chichester, 2008.
20	Kim SY, Park JE, Lee YJ, Seo HJ, Sheen SS, Hahn S, Jang BH and Son HJ: Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity. J Clin Epidemiol. 66:408–414. 2013.PubMed/NCBI View Article : Google Scholar
21	Rao G, Lopez-Jimenez F, Boyd J, D'Amico F, Durant NH, Hlatky MA, Howard G, Kirley K, Masi C, Powell-Wiley TM, et al: Methodological standards for meta-analyses and qualitative systematic reviews of cardiac prevention and treatment studies: A scientific statement from the American heart association. Circulation. 136:e172–e194. 2017.PubMed/NCBI View Article : Google Scholar
22	Sharma VK, Fraulin FO, Dumestre DO, Walker L and Harrop AR: Beta-blockers for the treatment of problematic hemangiomas. Can J Plast Surg. 21:23–28. 2013.PubMed/NCBI View Article : Google Scholar
23	Sun L, Sun B, Ma Y, et al: Comparison of the efficacy and safety of propranolol and atenolol in the treatment of infant hemangioma. Progress Modern Biomed. 18:108–112. 2018.
24	de Graaf M, Raphael MF, Breugem CC, Knol MJ, Bruijnzeel-Koomen CA, Kon M, Breur JM and Pasmans SG: Treatment of infantile haemangiomas with atenolol: Comparison with a historical propranolol group. J Plast Reconstr Aesthet Surg. 66:1732–1740. 2013.PubMed/NCBI View Article : Google Scholar
25	Dakoutrou M, Alexopoulos A, Miligkos M, Georgiadou E, Kanaka-Gantenbein C and Kakourou T: Atenolol treatment for severe infantile hemangiomas: Comparison with a propranolol group of our centre. J Eur Acad Dermatol Venereol. 33:e199–e200. 2019.PubMed/NCBI View Article : Google Scholar
26	Wang Q, Xiang B, Ji Y, Li F, Xu Z and Zhong L: Propranolol versus atenolol in the treatment of infantile hemangioma: A comparative study. Chin J Dermatol. 49:683–687. 2016.
27	Ashraf R, Mahajan R, Abas M, Handa S, Sinha A, De D and Sachdev N: Comparing the clinical, radiologic and biochemical effectiveness of atenolol and propranolol in the treatment of infantile hemangioma-a randomized controlled trial. Social Science Research Network, Rochester, NY, 2019. https://ssrn.com/abstract=3353380.